Gallo's corporate plans

Robert Gallo, who is leaving the NIH to lead the Institute of Human Virology at the University of Maryland, also plans to create a biotech company to link his highly academic research to the clinic.

In an interview with BioCentury after announcing his planned departure from the NIH last week, Gallo sketched out his model for an associated biotechnology company,Virex, where he expects to be chief scientific advisor.